Background  Treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) is difficult with low response rates. Aim  To assess the safety and efficacy of pegylated-interferon (PEG-IFN) alfa-2b + ribavirin (RBV) in patients with post-LT recurrent genotype-1 HCV and to establish stopping rules according to response. Methods  Fifty-three patients with post-LT HCV recurrence were enrolled. Patients received PEG-IFN alfa-2b 1.0 μ/kg/week plus RBV 8–10 mg/kg/day for 24 weeks. Those with ‘early virological response at week 24’ (EVR24) continued treatment for 24 weeks (group A). Patients without EVR24 were randomized to continue (group B) or to discontinue (group C). Results  Overall sustained virological response (SVR) was 26% (14/53). Alanine aminotransferase, rapid virological response, EVR12, EVR24, undetectable serum HCV-RNA at weeks 12 (cEVR12) and 24 (cEVR24) were related to SVR. cEVR12 and cEVR24 (OR: 14.7; 95% CI: 2.02–106.4) were independent predictors of SVR. All patients with SVR, had cEVR12. No patient in groups B and C achieved end-of-treatment response. One patient in group B had SVR. Conclusions  Pegylated-interferon alfa-2b was effective in one of four of patients with HCV genotype 1 after LT. Treatment should be discontinued in patients with no virological response at week 12. Further studies are needed to evaluate whether a longer treatment period may be beneficial in patients with ≥2 log10 drop in HCV-RNA at week 24

Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation / Lodato, F; Berardi, S; Gramenzi, A; Mazzella, G; Lenzi, M; Morelli, Mc; Tame, Mr; Piscaglia, F; Andreone, P; Bologna Liver Transplantation Group (BLTG), [. . .; Ballardini, G; Bernardi, M; Bianchi, Fb; Biselli, M; Bolondi, L; Cescon, M; Colecchia, A; D'Errico, A; Del Gaudio, M; Ercolani, G; Grazi, Gl; Grigioni, W; Lorenzini, S; Pinna, Ad; Ravaioli, M; Roda, E; Sama, C; Vivarelli, M.; ], . .. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - 28:4(2008), pp. 450-457. [10.1111/j.1365-2036.2008.03761.x]

Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation

Andreone P;Bernardi M;Colecchia A;Pinna AD;Sama C;
2008

Abstract

Background  Treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) is difficult with low response rates. Aim  To assess the safety and efficacy of pegylated-interferon (PEG-IFN) alfa-2b + ribavirin (RBV) in patients with post-LT recurrent genotype-1 HCV and to establish stopping rules according to response. Methods  Fifty-three patients with post-LT HCV recurrence were enrolled. Patients received PEG-IFN alfa-2b 1.0 μ/kg/week plus RBV 8–10 mg/kg/day for 24 weeks. Those with ‘early virological response at week 24’ (EVR24) continued treatment for 24 weeks (group A). Patients without EVR24 were randomized to continue (group B) or to discontinue (group C). Results  Overall sustained virological response (SVR) was 26% (14/53). Alanine aminotransferase, rapid virological response, EVR12, EVR24, undetectable serum HCV-RNA at weeks 12 (cEVR12) and 24 (cEVR24) were related to SVR. cEVR12 and cEVR24 (OR: 14.7; 95% CI: 2.02–106.4) were independent predictors of SVR. All patients with SVR, had cEVR12. No patient in groups B and C achieved end-of-treatment response. One patient in group B had SVR. Conclusions  Pegylated-interferon alfa-2b was effective in one of four of patients with HCV genotype 1 after LT. Treatment should be discontinued in patients with no virological response at week 12. Further studies are needed to evaluate whether a longer treatment period may be beneficial in patients with ≥2 log10 drop in HCV-RNA at week 24
28
4
450
457
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation / Lodato, F; Berardi, S; Gramenzi, A; Mazzella, G; Lenzi, M; Morelli, Mc; Tame, Mr; Piscaglia, F; Andreone, P; Bologna Liver Transplantation Group (BLTG), [. . .; Ballardini, G; Bernardi, M; Bianchi, Fb; Biselli, M; Bolondi, L; Cescon, M; Colecchia, A; D'Errico, A; Del Gaudio, M; Ercolani, G; Grazi, Gl; Grigioni, W; Lorenzini, S; Pinna, Ad; Ravaioli, M; Roda, E; Sama, C; Vivarelli, M.; ], . .. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - 28:4(2008), pp. 450-457. [10.1111/j.1365-2036.2008.03761.x]
Lodato, F; Berardi, S; Gramenzi, A; Mazzella, G; Lenzi, M; Morelli, Mc; Tame, Mr; Piscaglia, F; Andreone, P; Bologna Liver Transplantation Group (BLTG), [. . .; Ballardini, G; Bernardi, M; Bianchi, Fb; Biselli, M; Bolondi, L; Cescon, M; Colecchia, A; D'Errico, A; Del Gaudio, M; Ercolani, G; Grazi, Gl; Grigioni, W; Lorenzini, S; Pinna, Ad; Ravaioli, M; Roda, E; Sama, C; Vivarelli, M.; ], . .
File in questo prodotto:
File Dimensione Formato  
Post-OLT HCV.pdf

non disponibili

Dimensione 111.58 kB
Formato Adobe PDF
111.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Post-OLT HCV.pdf

non disponibili

Dimensione 111.58 kB
Formato Adobe PDF
111.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1237303
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 33
social impact